425: Obsidian Reports Positive Phase 2 Data for OBX-115

Obsidian Therapeutics announced positive Phase 2 clinical results for its lead TIL cell therapy candidate, OBX-115, in patients with advanced melanoma.

Summary

• Obsidian Therapeutics reported a 67% objective response rate (ORR) for OBX-115 in a Phase 2 study of patients with advanced melanoma.
• The study included 15 patients at the recommended phase 2 dose, with 2 complete responses and 8 partial responses.
• 80% of clinical responses were ongoing as of the median 4.3-month follow-up.
• The therapy demonstrated a favorable safety profile with no dose-limiting toxicities, no treatment-related mortality, and no ICU transfers.
• The company plans to pursue a single-arm accelerated approval pathway following alignment with the FDA.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, as the clinical data supports the viability of the lead asset and provides a clear regulatory path forward.

Positives

• Strong 67% ORR in a difficult-to-treat patient population, including 93% previously treated with doublet immune checkpoint inhibitors.
• Favorable safety profile with no treatment-related mortality or neurotoxicity (ICANS).
• Reduced treatment burden due to outpatient-compatible low-dose lymphodepletion and the elimination of IL2.
• Alignment reached with the FDA on key design elements for a single-arm accelerated approval pathway.

Negatives

• Small sample size of 15 patients at the recommended phase 2 dose.
• Short median follow-up period of 4.3 months, which may not fully capture long-term durability.
• Reliance on a single-arm study design for accelerated approval, which carries inherent regulatory risks.

Risks

• Potential failure to obtain regulatory approval for the accelerated pathway.
• Risks associated with the pending merger transaction between Galera Therapeutics and Obsidian.
• Uncertainty regarding the ability to secure sufficient capital to advance clinical programs.
• Dependence on the success of a single lead product candidate, OBX-115.
• Risks related to intellectual property protection and regulatory exclusivity.

Future Outlook

The company plans to begin treating patients in the registration-enabling cohort of the multicenter study in mid-2026 and is targeting an accelerated approval pathway for OBX-115 in advanced melanoma.

Management Comments

• Dr. Parameswaran Hari noted that the company is highly encouraged by the anticipated benefit in difficult-to-treat patients and has reached alignment with the FDA on key clinical trial design elements.

Industry Context

StockSavvy.ai notes that the shift toward IL2-sparing TIL therapies represents a significant trend in oncology, aiming to reduce the high toxicity burden associated with traditional cell therapies. Obsidian's focus on outpatient-compatible regimens positions them to compete with established players like Iovance Biotherapeutics.

Comparison to Industry Standards

• The 67% ORR compares favorably to historical benchmarks for late-line melanoma treatments, though direct comparison is limited by the small, single-arm study size.
• The safety profile, specifically the absence of IL2-related toxicities, differentiates OBX-115 from first-generation TIL therapies that require intensive inpatient management.

Stakeholder Impact

• Shareholders of Galera Therapeutics are impacted by the ongoing merger process and the clinical progress of the combined entity's lead asset.

Next Steps

• Oral presentation at the 2026 ASCO Annual Meeting on June 1, 2026.
• Initiation of the registration-enabling cohort in mid-2026.
• Completion of the merger transaction with Galera Therapeutics.

Key Dates

Recommendation

The combination of positive clinical efficacy, a clear regulatory pathway for accelerated approval, and the potential for a reduced-burden treatment regimen makes this a compelling development for investors in the oncology space.

Keywords

Obsidian Therapeutics, OBX-115, TIL cell therapy, melanoma, clinical trial, immunotherapy, Galera Therapeutics, ASCO